No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AVPT240517C5000
- 2.95
- 0.000.00%
15min DelayClose May 2 11:41 ET
0.00High0.00Low
0.00Open2.95Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover292.78%IV2.47%PremiumMay 17, 2024Expiry Date3.10Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9053Delta0.0469Gamma2.45Leverage Ratio-0.0365Theta0.0009Rho2.22Eff Leverage0.0021Vega
Intraday
- 5D
- 1D
News
Express News | AvePoint Announces First Quarter 2024 Financial Results
Express News | AvePoint Q1 Operating Expenses USD 57.293 Million
Insider Sale: Chief Legal Officer Brian Brown Sells 20,000 Shares of AvePoint Inc (AVPT)
AvePoint(AVPT.US) Officer Sells US$157.2K in Common Stock
$AvePoint(AVPT.US)$ Officer Brown Brian Michael sold 20,000 shares of common stock on May 1, 2024 at an average price of $7.86 for a total value of $157.2K.Source: Announcement What is statement of ch
AvePoint to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ:AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, today announced that members of the company's executive
AvePoint, Inc. (NASDAQ:AVPT) Adds US$81m in Market Cap and Insiders Have a 37% Stake in That Gain
Key Insights Insiders appear to have a vested interest in AvePoint's growth, as seen by their sizeable ownership The top 6 shareholders own 51% of the company Institutions own 36% of AvePoint A
Comments
$AvePoint(AVPT.US$ should have sold this prior to merger 🤣
1
1
Gainers
• $Anaplan(PLAN.US$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess(GES.US$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective(MCG.US$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics(SRNE.US$ +2.3% (reports promising results with a universal...
• $Anaplan(PLAN.US$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess(GES.US$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective(MCG.US$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics(SRNE.US$ +2.3% (reports promising results with a universal...
19
1
Upgrades
• $Air Products & Chemicals(APD.US$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc(ASB.US$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries(AWI.US$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry(BB.US$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares(CBSH.US$: Wells Fargo Upgrades to Equal Weight from...
• $Air Products & Chemicals(APD.US$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc(ASB.US$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries(AWI.US$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry(BB.US$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares(CBSH.US$: Wells Fargo Upgrades to Equal Weight from...
14
1
$Microsoft(MSFT.US$ $AvePoint(AVPT.US$
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
13
3
$AvePoint(AVPT.US$ can you get out of reverse now! please, my losses increase daily.
6
1
Read more
Steven J : Who did they merge with?